Please wait while the transcript is being prepared...
0:00
This is Scott Halstead, and I'm going to be giving
two lectures on current dengue vaccine development.
I have been an officer of the
Dengue Vaccine Initiative located
at the International
Vaccine Institute
in Seoul, Korea for
more than 10 years.
The first lecture describes the
current status of dengue vaccine
development, and the second
will describe the uses
and deployment of these vaccines.
0:26
So the lecture will
cover three topics.
One is the scope of the
problem of dengue in the world.
And do we need a
tetravalent dengue vaccine?
And then we'll describe
each of the current vaccines
that are in development, and
their development status.
0:45
So scope of the problem.
0:49
As you can see from this
recent global map of the Earth,
there is a belt in
the tropical regions
around the entire globe were
dengue viruses are transmitted.
This amounts to transmission
in 128 different countries.
And this slide shows the
intensity of transmission.
The blue dots are actually reports
either from individual countries
or published in the literature.
So those are indications
of current activity.
But the colors on the
chart, intense red meaning
endemic transmission to
green meaning no transmission
give you a quick idea.
You can see that most of
the temperate countries
do not currently have
dengue transmission,
either in northern or
southern hemisphere.
1:35
Now here's the bad
news, which is A, there
are four different dengue viruses.
They've all evolved from a
common ancestor to be 30% to 40%
genetically different.
And although they perhaps all
originated in Southeast Asia,
they have spread around the world.
And now in each of the
endemic areas of the world,
in the American, African, and Asian
tropics, all of the four viruses
are in circulation.
